Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Medicines Company (MDCO)

Medicines Company (MDCO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,768,482
  • Shares Outstanding, K 79,723
  • Annual Sales, $ 6,140 K
  • Annual Income, $ -123,160 K
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MDCO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.98
  • Most Recent Earnings -0.72 on 10/30/19
  • Next Earnings Date 02/26/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.90
  • Number of Estimates 6
  • High Estimate -0.74
  • Low Estimate -1.19
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -34.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.88 +1.22%
on 12/05/19
84.98 -0.09%
on 01/03/20
+0.80 (+0.95%)
since 12/03/19
3-Month
48.96 +73.41%
on 10/04/19
84.98 -0.09%
on 01/03/20
+34.87 (+69.70%)
since 10/03/19
52-Week
17.81 +376.70%
on 01/04/19
84.98 -0.09%
on 01/03/20
+67.04 (+375.36%)
since 01/03/19

Most Recent Stories

More News
Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

Grant Blouse, Ph.D., M.Sc. appointed chief scientific officer

MDCO : 84.90 (-0.07%)
CBIO : 4.19 (+2.95%)
Salvia BioElectronics appoints Dr Alan Levy as Chairman

EINDHOVEN, , /PRNewswire/ --  ("Salvia"), a neurostimulation platform company targeting chronic migraine, announces today the appointment of Dr as Chairman of the Board of Directors.  

HPQ : 29.09 (+0.76%)
MDCO : 84.90 (-0.07%)
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH - A Healthcare Transforming Medicines Company

and , /PRNewswire/ -- ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in and access to a site in , which will house its principal...

MDCO : 84.90 (-0.07%)
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives

Attralus Therapeutics today announced the appointment of Mark Timney as the company's Chief Executive Officer and a member of its Board of Directors. Timney brings to Attralus more than 30 years of leadership...

MDCO : 84.90 (-0.07%)
NVS : 92.27 (-0.13%)
Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

Company plans Phase 1 trial initiations across three novel degrader programs by end of 2021

MDCO : 84.90 (-0.07%)
KYMR : 59.23 (-1.58%)
Global Antisense & RNAi Therapeutics Market Report 2020-2030 with COVID-19 Growth and Change Impact Insights

, /PRNewswire/ -- The report has been added to offering.

ATHJF : 0.1540 (+2.67%)
BNIKF : 0.0180 (+11.11%)
GSK : 40.26 (+0.30%)
IONS : 37.85 (+1.91%)
MDCO : 84.90 (-0.07%)
NVS : 92.27 (-0.13%)
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic complement regulator programs on Monday, December 14, 2020 at 12:00...

MDCO : 84.90 (-0.07%)
CBIO : 4.19 (+2.95%)
Shares of MDCO Up 19.9% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Medicines Comp (NASDAQ:MDCO) on November 19th, 2019 at $70.84. In approximately 12 months, Medicines Comp has returned 19.86% as of today's recent price of $84.90.

MDCO : 84.90 (-0.07%)
Medicines Comp Up 19.9% Since SmarTrend Uptrend Call (MDCO)

SmarTrend identified an Uptrend for Medicines Comp (NASDAQ:MDCO) on November 19th, 2019 at $70.84. In approximately 11 months, Medicines Comp has returned 19.86% as of today's recent price of $84.90.

MDCO : 84.90 (-0.07%)
Medicines Comp Has Returned 19.9% Since SmarTrend Recommendation (MDCO)

SmarTrend identified an Uptrend for Medicines Comp (NASDAQ:MDCO) on November 19th, 2019 at $70.83. In approximately 11 months, Medicines Comp has returned 19.86% as of today's recent price of $84.90.

MDCO : 84.90 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

The Medicines Company is a biopharmaceutical company driven by an overriding purpose-to save lives and alleviate suffering by developing solutions for diseases with vast economic and social consequences. The Company's mission is to create transformational solutions to address the most pressing healthcare...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 85.02
1st Resistance Point 84.96
Last Price 84.90
1st Support Level 84.86
2nd Support Level 84.82
3rd Support Level N/A

See More

52-Week High 84.98
Last Price 84.90
Fibonacci 61.8% 59.32
Fibonacci 50% 51.40
Fibonacci 38.2% 43.47
52-Week Low 17.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar